Evidence map›Paper›PMID 34789766›Full record

ArticleScientific reports2021

SPME-LC/MS-based serum metabolomic phenotyping for distinguishing ovarian cancer histologic subtypes: a pilot study.

Mariola Olkowicz, Hernando Rosales-Solano, Vathany Kulasingam, Janusz Pawliszyn

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Early Detection of Ovarian Cancer.Cold Spring Harbor perspectives in medicine · 2023
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Mariola OlkowiczDepartment of Chemistry, University of Waterloo, Waterloo, ON, N2L 3G1, Canada.
Hernando Rosales-SolanoDepartment of Chemistry, University of Waterloo, Waterloo, ON, N2L 3G1, Canada.
Vathany KulasingamDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, M5S 1A8, Canada. vathany.kulasingam@uhn.ca.
Janusz PawliszynDepartment of Chemistry, University of Waterloo, Waterloo, ON, N2L 3G1, Canada. janusz@uwaterloo.ca.
University of Waterloo · CAUniversity of Toronto · CA

Funding

Natural Sciences and Engineering Research Council of Canada IRCPJ 184412-15
6 · The paper itself

Abstract

Epithelial ovarian cancer (EOC) is the most common cause of death from gynecological cancer. The outcomes of EOC are complicated, as it is often diagnosed late and comprises several heterogenous subtypes. As such, upfront treatment can be highly challenging. Although many significant advances in EOC management have been made over the past several decades, further work must be done to develop early detection tools capable of distinguishing between the various EOC subtypes. In this paper, we present a sophisticated analytical pipeline based on solid-phase microextraction (SPME) and three orthogonal LC/MS acquisition modes that facilitates the comprehensive mapping of a wide range of analytes in serum samples from patients with EOC. PLS-DA multivariate analysis of the metabolomic data was able to provide clear discrimination between all four main EOC subtypes: serous, endometrioid, clear cell, and mucinous carcinomas. The prognostic performance of discriminative metabolites and lipids was confirmed via multivariate receiver operating characteristic (ROC) analysis (AUC value > 88% with 20 features). Further pathway analysis using the top 57 dysregulated metabolic features showed distinct differences in amino acid, lipid, and steroids metabolism among the four EOC subtypes. Thus, metabolomic profiling can serve as a powerful tool for complementing histology in classifying EOC subtypes.

Indexed as

MetabolomePhenotypeBiomarkers, TumorCarcinoma, Ovarian EpithelialChromatography, LiquidFemaleHumansMass SpectrometryMetabolomicsOvarian NeoplasmsPilot ProjectsPrognosisSensitivity and SpecificitySolid Phase MicroextractionBiomarkers, Tumor

Identifiers

PMID34789766
PMCPMC8599860
OpenAlexW3212528796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.